With regard to the therapeutic potential of WP1130 and b-AP15, although both compounds have been shown to promote tumor cell apoptosis in preclinical models [43,44], DUB inhibitors with narrower target specificity, such as b-AP15, might be more easily amenable to clinical development, since DUB inhibitors with broader specificity, such as WP1130, may be more prone to cause unwanted side effects that are difficult to predict. This evidence concerns the gene ZUP1 and neoplasm.